CG Oncology, Inc. Common stock
CGON · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $0 | $0 | $0 |
| % Growth | – | -100% | -88.6% | – |
| Cost of Goods Sold | $2 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 5.3% | – | 100% | 100% |
| R&D Expenses | $28 | $31 | $27 | $27 |
| G&A Expenses | $23 | $0 | $15 | $12 |
| SG&A Expenses | $23 | $17 | $15 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $51 | $49 | $42 | $39 |
| Operating Income | -$51 | -$49 | -$42 | -$38 |
| % Margin | -3,069% | – | -81,161.5% | -8,344.1% |
| Other Income/Exp. Net | $7 | $7 | $8 | $6 |
| Pre-Tax Income | -$44 | -$41 | -$34 | -$32 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$44 | -$41 | -$34 | -$32 |
| % Margin | -2,629.5% | – | -66,253.8% | -6,973.2% |
| EPS | -0.57 | -0.54 | -0.45 | -0.49 |
| % Growth | -5.6% | -20% | 8.2% | – |
| EPS Diluted | -0.57 | -0.54 | -0.45 | -0.49 |
| Weighted Avg Shares Out | 77 | 76 | 76 | 65 |
| Weighted Avg Shares Out Dil | 77 | 76 | 76 | 65 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $7 | $8 | $6 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$43 | -$41 | -$42 | -$38 |
| % Margin | -2,604.6% | – | -81,115.4% | -8,344.1% |